All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Ocular Therapeutix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

Ocular, Regeneron Shift Focus of Eye Treatment Collaboration

Contact the Supplier

Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 15, 2020

Details:

The collaboration will research and develop an extended delivery formulation of aflibercept via the suprachoroidal space.

Dyno Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

Dyno Therapeutics Emerges from Stealth to Transform Gene Therapy using Artificial Intelligence

Contact the Supplier

Lead Product(s): AAV vectors gene therapy

Therapeutic Area: Ophthalmology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Harvard University

Deal Size: $2000.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration May 11, 2020

Details:

CapsidMap™ enables the design of novel Adeno-Associated Virus (AAV) vectors that significantly improve upon current approaches to gene therapy and expand the scope of accessible diseases.